Do you want to read an article? Please log in or register.
Real-World Data on Osimertinib-Associated Cardiac Toxicity
Lung Cancer
RECOMMENDED
Related content
Lung Cancer
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)
Clin Lung Cancer
Sakata Y, Saito G, Sakata S, Yamaguchi T, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Uchida J, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T
doi: 10.1016/j.cllc.2025.05.015
Lung Cancer
Real-World Effectiveness of Second-Line Therapies in Advanced Non-Small Cell Lung Cancer: Insights From Propensity-Weighted Comparative Analyses of Longitudinal EHR Data
Clin Lung Cancer
Hettinger GCN, Long Q, Parikh RB
doi: 10.1016/j.cllc.2025.09.010
RECOMMENDED
Further Publications
Multicentre, real-world data of next-generation computer-assisted vacuum aspiration thrombectomy in acute pulmonary embolism
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res
Sławek-Szmyt S, Stępniewski J, Kurzyna M, Klaudel J, Kuliczkowski W, Lewandowski M, Grabka M, Roik M, Ordiene R, Jankiewicz S, Kopeć G, Darocha S, Mroczek E, Widecka K, Kurzyna P, Lesiak M, Pruszczyk P, Araszkiewicz A
doi: 10.1186/s12931-025-03162-4
RECOMMENDED
Lung Cancer
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Barsouk A, Elghawy O, Watts A, Reed-Guy L, Tompkins W, Chandrasekhara K, Grady CB, Iams W, Sun F, Liu G, Patel D, Nieva JJ, Marrone KA, Velcheti V, Liu SV, Patil T, Weiss J, Schwartzman W, Villaruz LC, Hermann A, Aisner DL, Hwang WT, Camidge DR, Sun L, Singh AP, Cohen RB, Aggarwal C, Langer CJ, Marmarelis ME
doi: 10.1016/j.lungcan.2025.108551
Lung Cancer
Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer
Sci Rep
Shin JE, Jung HA, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Shim BY
doi: 10.1038/s41598-024-81704-4
Lung Cancer
Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424L
Clin Lung Cancer
Kataoka S, Shukuya T, Ohtsu H, Miyawaki T, Fujimoto D, Hayashi H, Toi Y, Yokoyama T, Kato T, Yamaguchi T, Tanaka K, Miura S, Tamiya M, Tachihara M, Otsubo K, Sato Y, Ikeda S, Sakata S, Masuda T, Takemoto S, Yamamoto N, Okamoto I, Takahashi K
doi: 10.1016/j.cllc.2025.12.002
RECOMMENDED
Pulmonary Fibrosis
Lung Function Course of Patients With Pulmonary Fibrosis After Initiation of Anti-Fibrotic Treatment: Real-World Data From the Dutch National Registry
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respirology
Platenburg MGJP, Nakshbandi G, Moor CC, van Batenburg AA, Mostard RLM, Voortman M, Moonen L, Hekelaar N, Overbeek MJ, Bogaarts B, Kramer H, Marges E, Boerrigter BB, Bresser P, Schakenraad E, van der Maten J, van der Sloot CA, Walen S, Afonso PM, Wijsenbeek MS, Grutters JC
doi: 10.1111/resp.70030
Tuberculosis
Prevalence, clinical reasons and associated factors of extended treatment duration for drug susceptible tuberculosis - a real-world experience
Sci Rep
Liu CY, Chen RT, Shu CC, Lin SY
doi: 10.1038/s41598-025-97517-y
Lung Cancer
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database
Lung Cancer
Reale ML, Scattolin D, Vitale A, Passiglia F, Grisanti S, Macerelli M, Galetta D, Sini C, Minuti G, Citarella F, Roca E, Agustoni F, Dodi A, Cortinovis D, Belluomini L, Ricciardi S, Veccia A, Pizzutilo EG, Scotti V, Alì G, Mazzoni F, Russo A, Pignataro D, Bulotta A, Piovano P, Sergi C, Bettini A, Genova C, Pavan A, Soto Parra HJ, Ortega C, Pozzessere D, Vavalà T, Chiari R, Zannori C, D'Aveni A, Meoni G, Giannarelli D, Malapelle U, Novello S, Bria E, Pasello G
doi: 10.1016/j.lungcan.2025.108762